Of note, CYT-0851 is another RAD51 inhibitor that was recently approved for a phase 1/2 clinical study in various cancers (NCT03997968) after showing promise in preclinical models [70], thus may be a potential valuable alternative. Here, RAD51 is linked to cancer.